Study Results Support Survival Benefit of Atezolizumab-Based Therapy in NSCLC
Posted: Friday, July 13, 2018
Interim data from a study presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9002) demonstrated that atezolizumabplus chemotherapy (carboplatin and paclitaxel) plus bevacizumab provided an overall survival advantage in patients with nonsquamous non–small cell lung cancer (NSCLC). The updated data, from the ongoing phase III IMpower150 study, was provided by Mark A. Socinski, MD, Executive Medical Director of the Florida Hospital Cancer Institute, Orlando, Florida, and colleagues.
A total of 349 patients received atezolizumab, carboplatin, paclitaxel, and bevacizumab (arm A); 359 patients received atezolizumab, carboplatin, and bevacizumab (arm B); and 337 patients received carboplatin and bevacizumab (arm C).The patients in arm A lived longer than did those in arms B and C. An overall survival benefit was observed in all prespecified exploratory biomarker-selected subgroups analyzed, which included people with EGFR-positive and ALK-positive mutations who had received an appropriate targeted therapy as well as those with varying levels of PD-L1 expression or with negative PD-L1 expression.
JNCCN 360 previously reported on data from the IMpower150 study presented at the 2018 American Association for Cancer Research Annual Meeting; the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel delayed disease progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced nonsquamous NSCLC.
